Andere Sprachen Apontis Pharma AG

Aktien

A3CMGM

DE000A3CMGM5

APPH

Markt geschlossen - Xetra Andere Börsenplätze 17:36:16 03.07.2024			Nachbörslich 19:02:55
8.48 ^EUR	+0.95%		8.37	-1.30%

15.05.	Börse Frankfurt-News: Nebenwerte hinken weiter hinterher (Scale-Marktbericht)	DP
15.04.	Börse Frankfurt-News: Längst nicht jeder schwächelt (Scale-Marktbericht)	DP

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company	27.06.
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management	04.06.
DD: APONTIS PHARMA AG: Thomas Milz, buy	14.05.
DD: APONTIS PHARMA AG: be executive GmbH, buy	14.05.
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13.05.
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13.05.
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13.05.
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13.05.
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13.05.
Apontis Pharma : Earnings Call Q1/24 Presentation	08.05.
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed	08.05.
Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	05.04.
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast	05.04.
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications	05.04.
Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
APONTIS PHARMA expects profitable growth again in 2024	28.03.
Apontis Pharma : Earnings Call 2023 Presentation	28.03.
APONTIS PHARMA successfully completes performance and efficiency improvement program	06.02.
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published	09.11.
Apontis Pharma Provides Earnings Guidance for the Full Year 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Apontis Pharma AG

Aktien

A3CMGM

DE000A3CMGM5

APPH

Andere Sprachen

Filter